Effect of Intensive Blood Pressure Control on Cardiovascular Remodeling in Hypertensive Patients with Nephrosclerosis

Author:

Randall Otelio12ORCID,Kwagyan John1,Retta Tamrat1ORCID,Jamerson Kenneth3ORCID,Pogue Velvie4,Norris Keith5ORCID,Ketete Muluemebet1ORCID,Xu Shichen1,Greene Tom6,Wang Xuelei7,Agodoa Lawrence8

Affiliation:

1. Howard University, College of Medicine, Washington, DC 20060, USA

2. Division of Cardiovascular Disease, Department of Medicine, Washington, DC 20060, USA

3. University of Michigan, Ann Arbor, MI 48109, USA

4. Harlem Hospital Center, New York, NY 10037, USA

5. Martin Luther King/Charles R. Drew University of Medicine, Los Angeles, CA 90059, USA

6. University of Utah, Salt Lake City, UT 84112, USA

7. The Cleveland Clinic Foundation, Cleveland, OH 44195, USA

8. National Institute of Health, Bethesda, MD 66420, USA

Abstract

Pulse pressure (PP), a marker of arterial system properties, has been linked to cardiovascular (CV) complications. We examined (a) association between unit changes of PP and (i) composite CV outcomes and (ii) development of left-ventricular hypertrophy (LVH) and (b) effect of mean arterial pressure (MAP) control on rate of change in PP. We studied 1094 nondiabetics with nephrosclerosis in the African American Study of Kidney Disease and Hypertension. Subjects were randomly assigned to usual MAP goal (102–107 mmHg) or a lower MAP goal (≤92 mmHg) and randomized to beta-blocker, angiotensin converting enzyme inhibitor, or calcium channel blocker. After covariate adjustment, a higher PP was associated with increased risk of CV outcome (RR = 1.28, CI = 1.11–1.47,P<0.01) and new LVH (RR = 1.26, CI = 1.04–1.54,P=0.02). PP increased at a greater rate in the usual than in lower MAP groups (slope ± SE: 1.08 ± 0.15 versus 0.42 ± 0.15 mmHg/year,P=0.002), but not by the antihypertensive treatment assignment. Observations indicate that control to a lower MAP slows the progression of PP, a correlate of cardiovascular remodeling and complications, and may be beneficial to CV health.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Hindawi Limited

Subject

Nephrology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3